Cascadian Therapeutics (CASC) Reports Q3 Loss of $0.28/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Cascadian Therapeutics (CASC) Reports Q3 Loss of $0.28/Share

Cascadian Therapeutics Reports Third Quarter 2017 Financial Results

November 8, 2017 4:02 PM EST

SEATTLE, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ: CASC), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2017, and provided an update on tucatinib, an investigational oral, small molecule kinase inhibitor that is highly selective for HER2 and the Companys lead product in development for the treatment of HER2 overexpressing cancers.

Scott Myers, President and CEO of Cascadian Therapeutics, stated, We had a productive third quarter. Tucatinib was granted orphan drug designation for a second indication, HER2+ colorectal cancer and enrollment began for an... More